SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.

SOPHiA GENETICS was founded in 2011 as a startup at École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland.

Our mission is to provide equal access to knowledge and capabilities by democratizing data-driven medicine. We aim to be the global platform that allows healthcare professionals to leverage their expertise and work together around the world – unlocking the promise of data-driven medicine at scale.

Founders
Jurgi Camblong  ____  Chief Executive Officer
Pierre Hutter
Lars Steinmetz

Key People
Peter Casasanto  ____  Chief BioPharma Officer
Ken Freedman  ____  Chief Revenue Officer
Philippe Menu  ____  Chief Medical Officer
Ross Muken  ____  Chief Financial Officer & Chief Operating Officer
Kevin Puylaert  ____  Managing Director, EMEA
Manuela Valente  ____  Chief People Officer
Daan Van Well  ____  Chief Legal Officer, General Counsel
Abhimanyu Verma  ____  Chief Technology Officer
Zhenyu Xu  ____  Chief Scientific Officer

Office Locations
Rolle (Global Headquarters)  Switzerland
Boston  Massachusetts USA
Bidart  France

Employees
- 450 in 27 countries (1)
- 30% of employees hold a PhD
- 48% work in R&D

Finance
IPO Valuation: $1.1B
Ticker Symbol: SOPH on Nasdaq

(1) Data as of Jul 31, 2023
**About the SOPHiA DDM™ Platform**

SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different modalities. The SOPHiA DDM™ platform enables healthcare institutions to get quick, robust insights from their data. We apply our technology to areas such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support research and drug development efforts.

SOPHiA GENETICS’ data-sharing methodology also helps researchers and healthcare professionals work together as a community by sharing and leveraging patterns identified via artificial intelligence and machine learning. Our universal platform is designed to improve as we analyze more data over time.

The SOPHiA DDM™ platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently used by more than 750 hospital, laboratory, and biopharma institutions globally.¹

¹ as of December 31, 2021

**Awards and Recognition**

- **Swiss Biotech Association** 2023 Swiss Biotech Success Stories Award
- **Fast Company** World’s Most Innovative Companies for 2023
- **The Healthcare Technology Report** 2022 The Top 100 Healthcare Technology Companies
- **Built In Boston** 2022 Best Places to Work - Boston
- **BioAlps Association** 2021 Industry Award
- **Microsoft** 2021 Partner of the Year finalist
- **Healthcare Medtech Asia Awards** 2021 Hospital Partnership of the Year Australia & 2021 Oncology Product Innovation of the Year, Australia
- **Tech Tour Growth 50** 2019 Growth Award
- **Convergence in Oncology Summit** 2018 Salus Partner Excellence in HealthTech Award
- **MIT Tech Review** Ranked #30 in 50 Smartest Companies, 2017

**Media Inquiries:** media@sophiagenetics.com